5 research outputs found
ꡬ맀 ν μ 보νμμ΄ μΈμ§λΆμ‘°ν ν΄μμ λ―ΈμΉλ μν₯
νμλ
Όλ¬Έ (μμ¬)-- μμΈλνκ΅ λνμ : μλΉμνκ³Ό, 2016. 2. κΉλλ.κΈ°μ‘΄ μ 보νμμ λν μ°κ΅¬λ ꡬ맀λ₯Ό λͺ©μ μΌλ‘ νλ ꡬ맀 μ μ 보νμκ³Ό ꡬ맀μλμ μ§μ€λμ΄ μμμΌλ©° μλμ μΌλ‘ ꡬ맀 ν λ¨κ³μλ κ΄μ¬μ΄ λΆμ‘±νλ€. μλΉμμ μ νμ΄ νμ΄ λμ΄μ Έ μλΉμλ μ¬λ¬ μν μ€ νλλ₯Ό κ³ λ₯Ό μ μκ² λμμΌλ μ΄κ²μ μ€νλ € μλΉμμ μΈμ§λΆμ‘°νκ° μΌμ΄λ μ μλ νκ²½μ μ‘°μ±νλ€. μ΄λ¬ν λ°°κ²½μμ μΈμ§λΆμ‘°νμ μλΉμ λ§μ‘±μ κ΄κ³μ μν₯μ μ€ μ μμ κ²μΌλ‘ κ³ λ €λλ ꡬ맀 ν μ 보νμμ λν μ°κ΅¬κ° μ΄λ£¨μ΄μ§ νμκ° μλ€.
λ³Έ μ°κ΅¬λ μ§κΈκ» λ§μ΄ μ‘°λͺ
λμ§ μμλ ꡬ맀 ν μ 보νμμ μ¬μΈ΅μ μΌλ‘ μ κ·Όνμ¬ μλΉμ μ 보νμμ λν μ΄ν΄λ₯Ό μ¦μ§μν€κ³ ꡬ맀 ν μ 보νμμ λν μ΄λ‘ μ ν λλ₯Ό μ μνκ³ μ νλ€. ꡬ체μ μΈ μ°κ΅¬ λͺ©μ μ λ€μκ³Ό κ°λ€. 첫째, ꡬ맀 ν μ 보νμμ λν κΈ°μ΄μ μΈ μ 보λ₯Ό μ 곡νκ³ μ νμλ€. λμ§Έ, ꡬ맀 ν μ 보νμμ΄ κ΅¬λ§€ ν μΈμ§λΆμ‘°ν ν΄μμ μ΄λ ν μμ©μ νλμ§ μμλ³΄κ³ μ νμλ€. μ
μ§Έ, ꡬ맀 ν μ 보νμμ νκ³ μ νλ μκ΅¬κ° μΈμ§λΆμ‘°ν ν΄μμ μ΄λ ν μμ©μ νλμ§ μμλ³΄κ³ μ νμλ€.
μ΄μ λν λ°μ΄ν°λ₯Ό μμ§νκΈ° μν΄ μ¨λΌμΈμ ν΅ν μ 보νμ κ²½νμ΄ μΆ©λΆν κ²μΌλ‘ κ³ λ €λ 20-30λμ λ¨λ
μλ΅μλ₯Ό μ‘°μ¬ λμμλ‘ νμ νμ¬ μ¨λΌμΈ μ€λ¬Έμ‘°μ¬ λ°©μμΌλ‘ μ§ννμλ€. ꡬ맀 μν© μλ리μ€λ₯Ό ν΅ν΄ μΈμ§λΆμ‘°νλ₯Ό μ λνμμΌλ©° μ΄ ν μΈμ§λΆμ‘°ν μ λλ₯Ό μΈ‘μ νμλ€. μ νν μνκ³Ό κ³ λ €νμμΌλ μ ννμ§ μμ μνμ λν΄ μΌλ§λ μ 보νμ νκ³ μΆμμ§λ₯Ό μΆκ°μ μΌλ‘ λ¬Όμλ€. μ΄ ν, μλ΅μμ μ νμ μ§μ§νλ μ 보, μ νμ λ°λ°νλ μ 보, 무κ΄ν μ 보λ₯Ό ꡬλΆνμ¬ μλ리μ€λ‘ μ 곡νμμΌλ©° λ§μ§λ§μΌλ‘ λ§μ‘±μ μΈ‘μ νμ¬ μΈμ§λΆμ‘°ν ν΄μλ₯Ό μ΄ν΄λ³΄κ³ μ νμλ€.
μ΄λ₯Ό λΆμν κ²°κ³Ό, μλΉμ νΉμ±μ λ°λΌ ꡬ맀 ν μ 보νμ μκ΅¬κ° μμ΄νκ² λνλ¬λ€. μΈμ§λΆμ‘°ν μν©μμ ꡬ맀 ν νμμ 보 μ νκ³Ό ꡬ맀 ν μ 보νμμꡬμ λ°λΌ μλΉμ λ§μ‘±μ΄ μ‘°μ λμλ€. μ§μ§μ 보λ₯Ό ν΅ν΄ μλΉμλ μΈμ§λΆμ‘°νλ₯Ό ν΄μνμλ€. μ£Όλͺ©ν λ§ ν μ μ, λ°λ°μ 보 μμ μΈμ§λΆμ‘°νμμ λ§μ‘±μΌλ‘ κ°λ κΈ°μΈκΈ°λ₯Ό μλ§νκ² μ‘°μ νμλ€λ κ²μ΄λ€. ννΈ, λΉμ νλμ μ 보νμμꡬλ μΈμ§λΆμ‘°ν ν΄μμ λΆμ μ μΈ μν₯μ λ―Έμ³€λ€.
μΈμ§λΆμ‘°ν ν΄μμ μν₯μ μ£Όλ λ³μλ‘μ ꡬ맀 ν μ 보νμ μꡬμ ꡬ맀 ν νμ μ 보μ νμ΄ μ μλ―Έν¨μ΄ λ°νμ‘λ€. μλΉμ λ§μ‘±μ μλΉμμ ꡬ맀 ν νλμ μν₯μ μ£Όλ μ£Όμ λ³μμ΄λ€. λ°λΌμ ꡬ맀 ν μ 보νμ κ΄λ ¨ λ³μλ μλΉμμ λ§μ‘±, μ΄λ₯Ό λμ΄ μλΉμμ ꡬ맀 ν νλμλ μν₯μ μ€ μ μμ κ²μ΄λ€. λ³Έ μ°κ΅¬λ ꡬ맀μμ¬κ²°μ κ³Όμ μμ ꡬ맀 ν μ 보νμμ μ€μμ±κ³Ό μ΄μ λν μ΄ν΄μ νμ νμ₯μμΌ°λ€λ μ μμ μμλ₯Ό κ°μ§λ€.μ 1 μ₯ μ λ‘ 1
μ 1 μ λ¬Έμ μ κΈ° 1
μ 2 μ μ°κ΅¬λͺ©μ λ° μμ 5
μ 2 μ₯ μ΄λ‘ μ λ°°κ²½ 7
μ 1 μ ꡬ맀 ν μΈμ§λΆμ‘°ν 7
1. ꡬ맀 ν μΈμ§λΆμ‘°νμ κ°λ
7
2. ꡬ맀 ν μΈμ§λΆμ‘°νμ μν₯ μμΈ 10
3. ꡬ맀 ν μΈμ§λΆμ‘°νμ ν΄μ 11
μ 2 μ ꡬ맀 ν μ 보νμ 13
1. ꡬ맀 ν μ 보νμμ κ°λ
13
2. ꡬ맀 ν μ 보νμμ λν μ°κ΅¬ κ³ μ°° 15
3. μ 보νμνλμ μν₯μμΈ 17
μ 3 μ μλΉμ λ§μ‘± 20
1. μλΉμ λ§μ‘±μ κ°λ
20
2. μ 보νμκ³Ό μλΉμ λ§μ‘± 21
3. μΈμ§λΆμ‘°νμ μλΉμ λ§μ‘± 22
μ 3 μ₯ μ°κ΅¬ λ¬Έμ λ° μ°κ΅¬ λ°©λ² 23
μ 1 μ μ°κ΅¬λ¬Έμ λ° μ°κ΅¬λͺ¨ν 23
1. μ°κ΅¬λ¬Έμ 24
2. μ°κ΅¬λͺ¨ν 25
μ 2 μ μλ£μμ§ λ° μ°κ΅¬λ°©λ² 26
1. μ‘°μ¬λμ λ° μλ£μμ§ λ°©λ² 26
2. μκ·Ή μλλ¦¬μ€ μ μ λ° μ μ°¨ 28
3. λ³μμ μ‘°μμ μ μ λ° μΈ‘μ 35
4. λΆμλ°©λ² 39
μ 3 μ μ‘°μ¬λμμμ νΉμ± 40
1. μ‘°μ¬λμμμ μΈκ΅¬Β·μ¬ννμ νΉμ± 40
2. μ°κ΅¬λμμμ μ¬λ¦¬μ νΉμ± 42
μ 4 μ₯ μ°κ΅¬ κ²°κ³Ό 43
μ 1 μ μΈκ΅¬μ¬νμ Β·μ¬λ¦¬μ νΉμ±μ λ°λ₯Έ ꡬ맀 ν μ 보νμ μꡬ 43
μ 2 μ ꡬ맀 ν μΈμ§λΆμ‘°νμ μλΉμ λ§μ‘±μ κ΄κ³ 47
μ 3 μ ꡬ맀 ν νμ μ 보μ νμ μ‘°μ ν¨κ³Ό 48
μ 4 μ ꡬ맀 ν μ 보νμμꡬμ μ‘°μ ν¨κ³Ό 51
μ 5 μ₯ κ²°λ‘ λ° μ μΈ 55
μ 1 μ μμ½ λ° κ²°λ‘ 55
μ 2 μ μ μΈ 60
μ°Έκ³ λ¬Έν 63
μ€λ¬Έμ§ 69
Abstract 77Maste
Enzyme-linked immunoassay for identification of quantitative difference of expression of fatty acid synthase in the blood of breast cancer patients
μκ³Όνκ³Ό/μμ¬[νκΈ]
μ λ°©μμ λ―Έκ΅μ΄λ μ λ½ λ± μ μ§κ΅κ°μμμ μ¬μ± μ μ€μμ κ°μ₯ νν μμΌλ‘ λ―Έκ΅ μ¬μ±μ μ 1μ μ¬λ§μμΈμ΄ λκ³ μλ€. μ΅κ·Όμλ λΉλ§κ³Ό κ΄λ ¨λ μ§λ°©μ° ν©μ± κ³Όμ κ³Ό μ λ°©μκ³Όμ μ°κ΄μ±μ΄ μ°κ΅¬λμλ€. λμ±μ΄ μ λ°©μμ μν λΆμλ‘ μλ €μ§ oncogenic antigen-519μ΄ 1994λ
Kuhajdaλ±μ μνμ¬ fatty acid synthase (FAS λλFASN) μμ΄ λ°νμ§λ©΄μ, μ λ°©μμ νμμλ‘μ FASμ λν μ°κ΅¬κ° μμλμλ€. FASNλ μΈν¬μ§λ΄ μ‘΄μ¬νλ ν¨μλ‘μ μ μμ μΈ μνμμλ μΈν¬μΈμ‘μ μ‘΄μ¬νμ§ μλλ€. κ·Έλ¬λ, μ λ°©μ μΈν¬μ£Όλ νΉμ§μ μΌλ‘ λ°°μμ‘μΌλ‘ FASλ₯Ό λΆλΉνλ€λ μ¬μ€μ΄ λ³΄κ³ λμμΌλ©°, μ΅κ·Όμλ μ λ°©μμ ν¬ν¨ν μ¬λ¬ μνμμ νμ‘μμ λΉμ μμ μΌλ‘ FASκ° λκ² κ²μΆλλ€κ³ λ³΄κ³ λμλ€. μ¦, μ λ°©μ νμμ 83%, μ 립μ μ νμμ 53%, λμ₯μ νμμ 90%, λμμ νμμ 40 % μμ νμ₯λ΄ λμ λλμ FASκ° κ²μΆλμλ€.λ³Έ μ°κ΅¬μμλ μ¬λμ νμ‘λ΄μ μλ λ¨λ°±μ§μ μμ μΈ‘μ νκΈ° μν΄μ, μ¬λμ μΈν¬μ£Ό(SkBr-3)μ μ₯μ κ°μμ λΆλ¦¬λ FAS λ¨λ°±μ§μ μ μ νκ³ , μ΄ λ¨λ°±μ§μ νμ€λλλ‘ μ€μ νμ¬, enzyme linked immunoassay λ°©λ² μ€μ νλμΈ two-site sandwich ELISA (2s-ELISA)λ₯Ό μ΄μ©ν FASμ μ λλ²μ μ€μ νμλ€. νμ λ¨λ°±μ§λ‘λ μ₯μ κ°μμ μΆμΆν FAS보λ€λ μ¬λ μΈν¬μ£Ό (SkBr-3)μμ λΆλ¦¬ν FASκ° λ controlλ‘μ μ μ©ν리λΌκ³ νλ¨λμλ€. λ°λΌμ, μ¬λμ νμ‘ μμ μλ FAS λ¨λ°±μ§λ§μ κ²μΆνκΈ° μνμ¬ μ¬μ‘°ν©λμ§ μμ λλ¬Ό μΈν¬μμ μ§μ λΆλ¦¬λ FAS λ¨λ°±μ§μ μ΄μ©νμ¬ λ§λ polyclonal anti-FAS ν체μ biotinμ΄ λΆμ monoclonal ν체λ₯Ό μ΄μ©ν 2s-ELISAλ₯Ό μλνμμ λ, μΈκ°μ νμ‘ μμ μλ FAS λ¨λ°±μ§μ κ²μΆλλ κ²μΌλ‘ νμΈλμλ€. λν, μ λ°©μ μΈν¬μ£Όλ€κ³Ό λ€λ₯Έ μΈν¬μ£Όλ€μ λ°°μμ‘μμλ FAS λ¨λ°±μ§μ μμ μΈ‘μ ν΄ λ³Έ κ²°κ³Ό SkBr-3, BT-474, MCF-7 μΈν¬μ£Όλ€μμ νΉμ΄μ μΌλ‘ λκ² κ²μΆλλ κ²μ νμΈλμλ€. λ§μ§λ§μΌλ‘, μ μμΈκ³Ό μ λ°©μ νμκ΅°μ νμ‘μμ FASμμ μΈ‘μ ν΄ λ³΄μμ λ, μ λ°©μ νμκ΅°μμ μ’ λ λ§μ μμ FAS λ¨λ°±μ§μ΄ κ²μΆ λμκ³ , λμ΄μ λ°λΌμλ 42μΈ μ΄μ 보λ€λ μ΄νμ νμκ΅°μμ FASμ μμ΄ μ’ λ κ²μΆ λλ κ²μ΄ νμΈλμλ€. μμΌλ‘, μμ κ°μ μ€νλ°©λ²μ λμ± κ°λ°νκ³ κ°μ ν¨μΌλ‘μ, μ λ°©μ νμμ μμμ 보μ λ°λΌ μ΄λ€ μ μν λ³νκ° μλμ§ μκ΄κ΄κ³λ₯Ό λΆμν΄ λ³Ό μ μκΈ°λ₯Ό κΈ°λν΄ λ³Έλ€.
[μλ¬Έ]
Breast cancer is the most frequent cancer among female cancers in advanced countries such as the U.S. or Europe, which has been the primary cause of death in U.S. women. Recently, relation between synthesis of fatty acid and breast cancer was studied as associated with fatness. Furthermore, as oncogenic antigen-519 known as a prognostic factor of breast cancer was founded to be fatty acid synthase (FAS or FASN) by Kuhajda et al. in 1994, studies on FAS, which is an indicator of breast cancer, were begun. The FAS, an enzyme existing in the cytoplasm, does not exist in the extra cellular fluid (ECF) under normal condition. However, it was reported that the breast cancer cell lines would specifically secret FAS as culture medium, and recently that FAS was abnormally detected at high levels in the blood of cancer cases including breast cancer; a high level of FAS in plasma was detected from 83% of breast cancer patients, 53% of prostate cancer patients, 90% of colon cancer patients, and 40% of ovarian cancer patients.In this study, to measure an amount of protein in human blood, FAS protein separated from the human cell line (SkBr-3) and the rat liver was purified, the protein was set at standard concentration, and FAS assay was set up with two-site sandwich ELISA (2s-ELISA), one of enzyme linked immunoassays. It was deemed that as antigen protein, rather FAS separated from the human cell line (SkBr-3) than that extracted from the mouse liver would be more useful as control. Therefore, when 2s-ELISA was attempted using both the polyclonal anti-FAS antibody made with FAS protein directly separated from non-recombined animal cell to detect only FAS protein in human blood and the monoclonal antibody attached with biotin, FAS protein in human blood was detected. Also, after an amount of FAS protein was measured in the culture medium of different cell lines from breast cancer cell lines, it was specifically detected at a high level in the SkBr-3, BT-474, and MCF-7 cell lines. Finally, when an amount of FAS was measured in the blood of healthy persons and patients with breast cancer, a more amount of FAS protein was detected in breast cancer patients, and regarding age, a more amount of FAS was detected in patients aged above 42 than those aged under 42.The author expects that correlation of significant changes with clinical information of breast cancer patients will be analyzed by further developing and improving the above mentioned experimental method.prohibitio